<table>
<thead>
<tr>
<th>Name:</th>
<th>Healthcare Provider’s Name (e.g., neurologist)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phone Number:</td>
<td>Healthcare Provider’s Name (e.g., primary care provider)</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>For medical records or lab tests</td>
</tr>
</tbody>
</table>

For more information on LEMTRADA, including important risks, please refer to the Prescribing Information and/or [www.LEMTRADA.com](http://www.LEMTRADA.com).

For information on LEMTRADA or the LEMTRADA REMS Program, call 1-855-676-6326.

LEMTRADA and Genzyme are registered trademarks of Genzyme Corporation.

©2015 Genzyme Corporation, a Sanofi company. All rights reserved. US.MS.LEM.14.10.001-v2

Reference ID: 3821900
Important information to know about LEMTRADA

<<insert your name>>

has been treated with LEMTRADA, a treatment for multiple sclerosis (MS), which lowers the number of circulating white blood cells for a period of time after treatment and also affects the immune system. Therefore, the patient is part of a laboratory monitoring program that continues for 4 years after his/her last treatment.

Reference ID: 3821900

LEMTRADA treatment can increase the risk of:
Autoimmune conditions such as:
- A bleeding problem called immune thrombocytopenia (ITP)
- Other blood disorders (including neutropenia, hemolytic anemia, and pancytopenia)
- Disorders of the thyroid gland (hypo/hyperthyroidism)
- Kidney disorders (nephropathies, including anti-glomerular basement membrane [anti-GBM] disease)

Infusion reactions (may occur more than 24 hours after the infusions, such as):
- Hypersensitivity reactions (including anaphylaxis)
- Fever
- Hives
- Irregular heartbeat
- Nausea
- Chest pain
- Low blood pressure

Malignancies such as:
- Thyroid cancer
- Melanoma
- Lymphoproliferative disorders and lymphoma